$OKLO

Narayanadas Vivek sold $11K of OKLO

Narayanadas Vivek (General Counsel & Secretary) sold 288 shares of Oklo Inc. (OKLO) at $37.29 on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Narayanadas Vivek
Published Oct 8, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OKLO
Bearish
high confidence
Mentioned
$OKLO
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OKLOBearishLow
01

Why it matters

The transaction is modest in size and unlikely to move the stock significantly, but it provides transparency on insider holdings.

02

Market read

A routine insider sale with limited price impact; primarily of interest to shareholders monitoring insider activity.

03

What to watch

Potential upcoming corporate actions not disclosed could influence insider behavior.

Relevance 2/10Novelty 2/10Timing: post‑filing today

Background

SEC Form 4 filing discloses an insider's open‑market sale under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$OKLOBearishHigh confidence
Context

General Counsel sold 288 shares for $10.7K via a 10b5‑1 plan, reducing his stake to 8,446 shares.

Expected impact

likely pressure as the market prices in the insider sale

Evidence & confidence

The sale is small relative to float and disclosed via a Form 4, suggesting limited market impact.

Market effects

None

None

None

Counterpoint

The sale may be routine and not indicative of broader concerns.

Key entities

  • Narayanadas Vivek

    General Counsel & Secretary of Oklo Inc., insider seller.

  • Oklo Inc.

    Nuclear technology firm (ticker OKLO).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SMRLowAI 8/10

NuScale Power Falls 7% as 10-Year Treasury Yield Climbs to 5.26%; Energy Fuels Drops 9%, Oklo Slides 5%

NuScale Power (SMR) fell 7% to $6.04, Energy Fuels (UUUU) dropped 9% to $8.43, and Oklo (OKLO) slid 5% to $30.11 as 10-year Treasury yields rose to 5.26%. The Global X Uranium ETF (URA) declined 4%, outpacing the broader market's 0.8% drop. Rising yields impact long-duration assets like nuclear developers, affecting both valuation and project financing costs.

$OKLOHigh

Oklo Launched Another $1 Billion Stock Sale. Here's How Much Dilution Shareholders Have Absorbed Since It Went Public.

Oklo (NYSE: OKLO), a nuclear energy company, launched a $1 billion stock sale on Sept. 11, adding to prior sales since its May 2024 SPAC merger. Outstanding shares increased 58% to 192.3 million, diluting early shareholders by 37%. Despite a 311% share price increase, Oklo's stock hit a 52-week low on Oct. 8, requiring more shares to raise the same capital.

$GOOGHighAI 8/10

Google Signed a Deal for Existing Reactors. So Why Did Oklo and NuScale Jump on the Constellation Energy News? The Read-Through Investors Are Missing.

Alphabet (GOOG, GOOGL) agreed to a 15-year and 20-year deal with Constellation Energy (CEG) for nuclear power, investing $4.3B in new capacity. Oklo (OKLO) and NuScale (SMR) shares also rose, despite no direct involvement. The companies develop small modular reactors (SMRs) for specific facilities, differing from Constellation's large-scale plants. Investors see broader nuclear energy growth, with SMRs expected to play a significant role by 2050, according to industry estimates.

$OKLOMed

Oklo (OKLO) Dropped, So What Is Driving Attention Now?

Oklo, a modular nuclear reactor company, focuses on selling long-term electricity contracts. It secured NRC approval for its Aurora design, has $1.6B cash, and partnerships with NVDA, META, and Switch. However, it reports $33M net loss, no revenue, and no operating plants. Market cap is $11B. Regulatory hurdles remain.

$OKLOMed

Oklo selected for DOE isotope production initiative

Oklo Inc. (NYSE:OKLO) was chosen by the U.S. Department of Energy to advance its Groves 2 Forge facility, focusing on producing lutetium-177 for cancer treatments. The project is part of the DOE’s initiative to boost domestic nuclear reactor development and isotope production. Oklo aims to transition from pilot to commercial-scale operations with regulatory approvals.